{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:20:41Z","timestamp":1785853241449,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00198-023-06831-6","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T22:01:22Z","timestamp":1686866482000},"page":"1653-1655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Zoledronic acid\u2013induced severe lymphopenia"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-674X","authenticated-orcid":false,"given":"Sava\u015f","family":"Karpuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"18","key":"6831_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822","journal-title":"N Engl J Med"},{"issue":"11","key":"6831_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/107999003322558782","volume":"23","author":"G Dicuonzo","year":"2003","unstructured":"Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F et al (2003) Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23(11):649\u2013654","journal-title":"J Interferon Cytokine Res"},{"key":"6831_CR3","doi-asserted-by":"publisher","first-page":"991913","DOI":"10.3389\/fendo.2022.991913","volume":"13","author":"K Lu","year":"2022","unstructured":"Lu K, Shi Q, Gong YQ, Li C (2022) Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Front Endocrinol (Lausanne) 13:991913","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6831_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","volume":"23","author":"JD Wark","year":"2012","unstructured":"Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J 3rd, Mesenbrink P et al (2012) Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23(2):503\u2013512","journal-title":"Osteoporos Int"},{"issue":"4","key":"6831_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00198-020-05653-0","volume":"32","author":"FP Chen","year":"2021","unstructured":"Chen FP, Fu TS, Lin YC, Lin YJ (2021) Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion. Osteoporos Int. 32(4):663\u2013670","journal-title":"Osteoporos Int."},{"issue":"8","key":"6831_CR6","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E (2011) Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 22(8):2337\u20132345","journal-title":"Osteoporos Int"},{"issue":"5","key":"6831_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jbmr.4802","volume":"38","author":"R Murdoch","year":"2023","unstructured":"Murdoch R, Mellar A, Horne AM, Billington E, Chan PL, Gamble GD et al (2023) Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial. J Bone Mineral Res 38(5):631\u2013638","journal-title":"J Bone Mineral Res"},{"issue":"9","key":"6831_CR8","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metabol 95(9):4380\u20134387","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"6831_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2403693","volume":"19","author":"S Mariani","year":"2005","unstructured":"Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S et al (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19(4):664\u2013670","journal-title":"Leukemia"},{"issue":"1","key":"6831_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jbmr.4434","volume":"37","author":"DM Black","year":"2022","unstructured":"Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T et al (2022) The interaction of acute-phase reaction and efficacy for osteoporosis after zoledronic acid: HORIZON pivotal fracture trial. J Bone Miner Res 37(1):21\u201328","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6831_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G et al (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41(6):326\u2013331","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"6831_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/art.1780231018","volume":"23","author":"OL Bijvoet","year":"1980","unstructured":"Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H et al (1980) APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23(10):1193\u20131204","journal-title":"Arthritis Rheum"},{"key":"6831_CR13","first-page":"bcr2015213786","volume":"2016","author":"P Kulkarni","year":"2016","unstructured":"Kulkarni P, Cushman T, Donthireddy V, Rao S (2016) Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis. Case Reports 2016:bcr2015213786","journal-title":"Case Reports."},{"issue":"12","key":"6831_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/annonc\/mdh478","volume":"15","author":"G Ferretti","year":"2004","unstructured":"Ferretti G, Petti M, Carlini P, Zeuli M, Picardi A, Meloni G et al (2004) Zoledronic acid-associated thrombotic thrombocytopenic purpura. Ann Oncol 15(12):1847\u20131848","journal-title":"Ann Oncol"},{"issue":"3","key":"6831_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00223-013-9750-6","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Adami S, Viapiana O, Tripi G, Zanotti R, Ortolani R et al (2013) Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif Tissue Int 93(3):249\u2013252","journal-title":"Calcif Tissue Int"},{"key":"6831_CR16","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.curtheres.2021.100634","volume":"94","author":"M Cui","year":"2021","unstructured":"Cui M, Zhang N, Zhang G, Han L, Yu LZ (2021) Investigation of intravenous zoledronic acid therapy on circulating lymphocyte subpopulation in patients with primary osteoporosis: a pilot study. Curr Ther Res 94:100634","journal-title":"Curr Ther Res"},{"issue":"4","key":"6831_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.12968\/hmed.2016.77.4.248","volume":"77","author":"C Psomadakis","year":"2016","unstructured":"Psomadakis C, Creamer A, Baynes C (2016) Carbimazole-induced pancytopaenia. Br J Hosp Med 77(4):248\u2013249","journal-title":"Br J Hosp Med"},{"issue":"1","key":"6831_CR18","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1210\/jc.2011-2221","volume":"97","author":"N Watanabe","year":"2012","unstructured":"Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M et al (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metabol 97(1):E49\u2013E53","journal-title":"J Clin Endocrinol Metabol"},{"issue":"3","key":"6831_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/trp.trp_45_20","volume":"17","author":"HR Nehara","year":"2020","unstructured":"Nehara HR, Gupta BK, Parmar S, Kumar V, Sihag D, Beniwal S (2020) Antithyroid drug-induced pancytopenia followed by acute lymphoblastic leukemia: a rare case. Thyroid Res Pract 17(3):149\u2013151","journal-title":"Thyroid Res Pract"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06831-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T08:04:09Z","timestamp":1692086649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06831-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6831"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06831-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}